Federico Giacobbe, Eduardo Valente, Arianna Morena, Marco Nebiolo, Giuseppe Giannino, Ovidio De Filippo, Francesco Bruno, Elena Isaevska, Lorenzo Richiardi, Mario Iannaccone, Giuseppe Biondi Zoccai, Francesco Burzotta, Fabrizio D'Ascenzo, Gaetano Maria De Ferrari
INTRODUCTION: Among different coronary stents implanted in High Bleeding Risk (HBR) patients with an indication for short antiplatelet therapy, no comparisons in terms of efficacy have been provided. METHODS: A Network Meta Analysis was performed including all randomized controlled trials comparing different coronary stents evaluated in HBR patients. Major Adverse Cardiovascular Events (MACEs) as defined by each included trial were the primary end point, whereas TLR (target lesion revascularization), TVR (target vessel revascularization), stent thrombosis and total and major (BARC3-5) bleedings were the secondary ones...
April 19, 2024: Catheterization and Cardiovascular Interventions